Lecturer
School of Pharmacy
Dept. of Pharmacology & Therapeutics
Cavanagh Pharmacy Building
College Road

T: +353-21-4901665
F: +353-21-4901656
E: anne.moore@ucc.ie
W: Web Page
">Web Page
Dr. Anne Moore graduated with a degree in Biochemistry University College Cork. She completed a PhD in HIV vaccine immunology with Professor Kingston Mills. Dr. Moore subsequently embarked upon post-doctoral work on defects in immune responses in HIV-infected individuals in the Wistar Institute in Philadelphia and further work on recombinant vaccines against viruses such as HIV and Ebola virus in Dr. Gary Nabel's lab then at the University of Michigan. As a senior immunologist in Prof. Adrian Hill's group in the University of Oxford, she developed several T cell inducing vaccine candidates against malaria and TB and was involved in clinical trials of these and other vaccine candidates in Oxford and malaria endemic areas in Africa. She took up a position as a Lecturer in Pharmacology, based in the School of Pharmacy, UCC in early 2007.

The central aim of Dr. Moore’s group is to develop and translate innovative vaccines and therapies to treat or prevent autoimmune or infectious diseases. Our research extends from basic cellular immunology to clinical translation.

ImmuPatch is a platform microneedle technology for transcutaneous drug and vaccine delivery. It provides the convenience of self-administration in a small, low-cost system and is protected by a family of patent applications.

IMMUPATCH DELIVERY TECHNOLOGY

ImmuPatch arrays incorporate ultrasharp microneedles that create microscopic openings in the top layer of the skin through which pharmaceutical agents or vaccines can diffuse.  Due to the geometry of the microneedles, nerve endings beneath the skin are not stimulated, and therefore, unlike competitors, ImmuPatch-enabled vaccine delivery is completely pain-free and results in minimal tissue damage. In comparison to other silicon microneedles, our patented ‘wet-etch’ fabrication methods are easily scalable to high-volume manufacturing levels and produce ultra-sharp microneedles that have been specifically designed to incorporate high safety margins.

Substantial pre-clinical research has demonstrated that solid microneedle ImmuPatch devices can induce augmented vaccine-induced immunity at significantly lower vaccine doses compared to needle-and-syringe delivery. We have identified key design parameters for optimum vaccination.

 

Immunization Programme Logistics.

The World Health Organization (WHO) recommends storing all vaccines in refrigerated or frozen conditions. Such narrow low temperature ranges require a highly organised and controlled system, termed ‘cold-chain’, which makes the process of distribution and storage complicated and expensive and it limits the shelf-life of the vaccine. Vaccine delivery costs can account for 54% of total cumulative. This is an unsustainable situation1, 2.

Stabilisation of vaccines as a solid dosage form, incorporated into a dissolvable microneedle would facilitate vaccine stockpiling and thus provide an immediate availability and simple global distribution of vaccine in routine as well as emergency, pandemic situations. A stabilising vaccine technology that also eliminates the requirement for reconstitution to a liquid state, for needles and syringes and for associated hazardous waste in addition to improved ease of use would have significant complementary benefits to immunization programmes. ImmuPatch is capable of delivering all of these advantages. Removal of cold-chain, in addition to removing syringes, safety boxes etc., by stabilising vaccines in ImmuPatch could result in an unprecedented cost decrease per fully immunized child of 33% in some countries. Cost-saving in immunization programmes would have significant commercial and clinical consequences.

 

Needle-and-Syringe based Drug and Vaccine Delivery

Currently the only method for delivering large medicinal molecules is the use of conventional needles and syringes for subcutaneous, intradermal or intramuscular administration. There are a large number of problems associated with these parenteral routes including;
a)  difficulty of use; reproducible administration to the dermis, using methods such as the ‘Mantoux’ technique,

b)  patient acceptability and compliance,

c)  pain and fear of needles, 

d)  hazardous sharps-waste; its storage and disposal costs and prevention of reuse

e)  the administration requirements for having trained personnel to correctly reconstitute drug/vaccine to liquid form and correctly  inject to indicated site (dermis, muscle etc).

 

ImmuPatch as a Solution:
We have developed two vaccine-loaded microneedle array technologies to overcome stability and distribution barriers. Our ‘Coated ImmuPatch’ is a device that has the drug or vaccine stably coated onto solid microneedles and ‘Dissolvable ImmuPatch’ incorporates a microneedle patch that is completely fabricated from vaccine-containing formulation and dissolves when inserted into the skin. Both of these vaccine-loaded microneedle array technologies are produced by a novel method, which avoids heating the drug or vaccine formulation, to precisely coat materials onto solid microneedle arrays or to generate solid, dissolvable microneedles. Our methods are specifically designed to be scalable to high-volume manufacturing levels and do not require the design or use of specialised, new equipment.  This ease of scale-up and versatility of use to a wide range of thermo-sensitive material provides our technology with a competitive advantage. We have acquired considerable expertise regarding the influence of microneedle surface chemistry, formulation composition and processing parameters on coating appearance and vaccine stabilisation. We have developed coating methods that can result in the vaccine being coated around the base of the microneedle or on the base and shaft of the microneedle, broadening our choice of coating designs. Finally, our vaccine-loaded microneedles can induce equivalent immunity to uncoated microneedle-administered vaccine in a mouse model.

Our dissolvable microneedles are prepared using an innovative method that enables the microneedle structure to be built with adequate mechanical strength to penetrate skin. The vaccine is embedded in the microneedle matrix that dissolves on contact with moisture in the epidermal and dermal layers. Our novel method of microneedle manufacture permits distinct layering of cargo materials into the microneedles in pre-determined orientations. This can result in episodic release of different active substances, physical seperation of different active substances or the use of protective layers. ImmuPatch is a simpler delivery device that eliminates cold chain, sharps waste and reduces the requirements for training in correct injection technique as well as in appropriate waste handling. It will have a significant effect on reducing the cost and increasing the success of immunization programmes.  Although we have focussed on vaccine delivery, we have generated considerable expertise and know-how on formulating thermolabile material onto or into microneedle arrays that can be transferred to developing drug-loaded ImmuPatch devices.


INFLUENZA VIRUS VACCINES:

In collaboration with the Jenner Institute, University of Oxford, we are developing a T cell-inducing universal flu vaccine that protects against multiple strains of the virus that cause both seasonal and pandemic infections. we generated. We have demonstrated that this strategy protects against challenge by multiple influenza virus strains and it is now being tested in Phase I and IIa clinical trials in the UK. Work within our group is defining pre-clinical correlates of protective systemic and mucosal immunity.

http://www.siliconrepublic.com/innovation/item/34842-towards-more-user-friendly/


IL-2:

The final focus of research is to modulate molecular signals delivered to T cells by interleukin-2 (IL-2). We previously demonstrated that a monoclonal antibody to the IL-2 receptor subunit, CD25, augments vaccine-induced immunity in mice and it safely and significantly increased vaccine immunogenicity in non-human primates. Based on our previous work and in collaboration with researchers at Trinity College Dublin, we have developed a novel method of inhibiting IL-2/CD25 interaction, independently of monoclonal antibodies and we are further exploring the modulation by CD25 of the immune system. We are developing this strategy initially as an immune therapy for autoimmune disorders.

Peer Reviewed Journals

 YearPublication
(2014)'Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles'
Paleco R., Vučen S.R., Crean A.M., Moore A.C., Scalia S (2014) 'Enhancement of the in vitro penetration of quercetin through pig skin by combined microneedles and lipid microparticles'. International Journal of Pharmaceutics, [DOI] [Details]
(2013)'Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1'
Lambe, T,Carey, JB,Li, YY,Spencer, AJ,van Laarhoven, A,Mullarkey, CE,Vrdoljak, A,Moore, AC,Gilbert, SC (2013) 'Immunity Against Heterosubtypic Influenza Virus Induced By Adenovirus And MVA Expressing Nucleoprotein And Matrix Protein-1'. Scientific Reports, 3 [DOI] [Details]
(2013)'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment'
Goodman AL, Forbes EK, Williams AR, Douglas AD, de Cassan SC, Bauza K, Biswas S, Dicks MD, Llewellyn D, Moore AC, Janse CJ, Franke-Fayard BM, Gilbert SC, Hill AV, Pleass RJ, Draper SJ. (2013) 'The utility of Plasmodium berghei as a rodent model for anti-merozoite malaria vaccine assessment'. Scientific Reports, 3 Globe icon [DOI] [Details]
(2013)'Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration'
McGrath MG, Vucen S, Vrdoljak A, Kelly A, O'Mahony C, Crean AM, Moore AC. (2013) 'Production of dissolvable microneedles using an atomised spray process: Effect of microneedle composition on skin penetration'. European Journal of Pharmaceutical Science, Epub ahead of print Globe icon [DOI] [Details]
(2013)'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'
Sonja R. Vucˇen, Gordana Vulet, Abina M. Crean, Anne C. Moore, Nenad Ignjatovic´and Dragan Uskokovic´ (2013) 'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'. Journal of Pharmacy and Pharmacology, 65 (8) Globe icon [DOI] [Details]
(2013)'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'
Vucen, SR,Vuleta, G,Crean, AM,Moore, AC,Ignjatovic, N,Uskokovic, D (2013) 'Improved percutaneous delivery of ketoprofen using combined application of nanocarriers and silicon microneedles'. Journal of Pharmacy and Pharmacology, 65 :1451-1462 [DOI] [Details]
(2012)'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'
Vrdoljak, A.,McGrath, M. G.,Carey, J. B.,Draper, S. J.,Hill, A. V.,O'Mahony, C.,Crean, A. M.,Moore, A. C. (2012) 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'. Journal of Controlled Release, 159 (11):34-4234 Globe icon [Details]
(2012)'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications'
Galvin P, Thompson D, Ryan K.B., McCarthy A, Moore AC, Burke CS, Dyson M, Maccraith BD, Gun'ko YK, Byrne MT, Volkov Y, Keely C, Keehan E, Howe M, Duffy C, Macloughlin R. (2012) 'Nanoparticle-based drug delivery: case studies for cancer and cardiovascular applications'. Cellular and molecular life sciences : CMLS, 69 (3):389-404 [DOI] [Details]
(2012)'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'
Vrdoljak, A,McGrath, MG,Carey, JB,Draper, SJ,Hill, AVS,O'Mahony, C,Crean, AM,Moore, AC (2012) 'Coated microneedle arrays for transcutaneous delivery of live virus vaccines'. Journal of controlled release : official journal of the Controlled Release Society, 159 (1):34-42 [DOI] [Details]
(2012)'Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'
Russell SE, Moore AC, Fallon PG, Walsh PT. (2012) 'Soluble IL-2Rα (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'. Plos One, 7 (10) [DOI] [Details]
(2012)'Soluble IL-2R alpha (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'
Russell, SE,Moore, AC,Fallon, PG,Walsh, PT (2012) 'Soluble IL-2R alpha (sCD25) Exacerbates Autoimmunity and Enhances the Development of Th17 Responses in Mice'. Plos One, 7 [DOI] [Details]
(2011)'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'
Carey, JB,Pearson, FE,Vrdoljak, A,McGrath, MG,Crean, AM,Walsh, PT,Doody, T,O'Mahony, C,Hill, AVS,Moore, AC; (2011) 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'. Plos One, 6 [DOI] [Details]
(2011)'Determination of parameters for successful spray coating of silicon microneedle arrays'
McGrath MG, Vrdoljak A, O'Mahony C, Oliveira JC, Moore AC, Crean AM; (2011) 'Determination of parameters for successful spray coating of silicon microneedle arrays'. International Journal of Pharmaceutics, 415 :140-149 [DOI] [Full Text] [Details]
(2011)'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'
Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Crean, A. M.,Walsh, P. T.,Doody, T.,O'Mahony, C.,Hill, A. V. S.,Moore, A. C. (2011) 'Microneedle Array Design Determines the Induction of Protective Memory CD8(+) T Cell Responses Induced by a Recombinant Live Malaria Vaccine in Mice'. Plos One, 6 (77) Globe icon [Details]
(2010)'Development of stabilized vaccines with needle-free devices for targeted skin immunization'
Moore, A. C., Crean, A. M., O¿Mahony; (2010) 'Development of stabilized vaccines with needle-free devices for targeted skin immunization'. European Pharmaceutical Review, 15 (6):56-60 Globe icon [Full Text] [Details]
(2009)'Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria'
Draper SJ, Goodman AL, Biswas S, Forbes EK, Moore AC, Gilbert SC, Hill AV; (2009) 'Recombinant viral vaccines expressing merozoite surface protein-1 induce antibody- and T cell-mediated multistage protection against malaria'. Cell Host and Microbe, 5 (1):95-105 Globe icon [DOI] [Details]
(2008)'Single dose protection against P. berghei by Simian Adenoviral vector using human CMV promoter containing Intron A'
Sridhar S., Reyes-Sandoval A., Draper S.J., Moore A.C., Gilbert S.C., Gao G.P., Wilson J.M. and Hill A.V.S. ; (2008) 'Single dose protection against P. berghei by Simian Adenoviral vector using human CMV promoter containing Intron A'. Journal of Virology, (82):3822-3833 Globe icon [Details]
(2008)'Multi-Stage Protection against Malaria using Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1'
Draper S.J, Moore A.C., Goodman A.L., Long C.A., Holder A.A., Gilbert S.C., Hill F., Hill A.V.S.; (2008) 'Multi-Stage Protection against Malaria using Recombinant Viral Vaccines Expressing Merozoite Surface Protein-1'. Nature medicine, (14):819-821 Globe icon [DOI] [Details]
(2008)'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria'
Schmidt NW, Podyminogin RL, Butler NS, Badovinac VP, Tucker BJ, Bahjat KS, Lauer P, Reyes-Sandoval A, Hutchings CL, Moore AC, Gilbert SC, Hill AV, Bartholomay LC, Harty JT.; (2008) 'Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria'. Proceedings of The National Academy of Sciences of The United States of America, 105 (37):14017-14022 Globe icon [DOI] [Details]
(2008)'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei'
Reyes-Sandoval A., Sridhar S., Berthoud T., Moore A.C., Harty J.T., Gilbert S.C., Gao G.P., Ertl H.C., Wilson J.M. and Hill A.V.S. ; (2008) 'Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei'. European Journal of Immunology, (38):732-741 Globe icon [DOI] [Details]
(2007)'Combination Vaccines; synergistic simultaneous induction of antibody and T cell immunity results in enhanced vaccine efficacy'
Moore A.C. Hutchings C.L.; (2007) 'Combination Vaccines; synergistic simultaneous induction of antibody and T cell immunity results in enhanced vaccine efficacy'. Expert Review of Vaccines, 6 (1):111-121 Globe icon [DOI] [Details]
(2007)'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge'
Hutchings C.L, Birkett A.J., Moore A.C., and Hill A.V.S. ; (2007) 'Combination of protein and viral vaccines induces potent cellular and humoral immune responses and enhanced protection from murine malaria challenge'. Infection and Immunity, (95):5819-5826 Globe icon [DOI] [Details]
(2006)'Safety, immunogenicity and efficacy of prime-boost immunization with recombinant pox viruses FP9 and modified vaccinia virus Ankara encoding the full length P. falciparum - circumsporozoite protein'
Walther M., Thompson F., Dunachie S., Keating M., Todryk S., Berthoud T., Andrews L., Andersen R., Moore A.C., Gilbert S.C., Poulton I., Dubovsky F., Tierney E., Correa S., Huntcooke A., Butcher G., Williams J., Sinden R.E., Hill A.V.S.; (2006) 'Safety, immunogenicity and efficacy of prime-boost immunization with recombinant pox viruses FP9 and modified vaccinia virus Ankara encoding the full length P. falciparum - circumsporozoite protein'. Infection and Immunity, (74):2706-2716 Globe icon [DOI] [Details]
(2006)'Safety of Recombinant Fowlpox Strain 9 and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage P. falciparum Malaria in Non-Immune Volunteers'
Webster D.P., Dunachie S., McConkey S., Poulton I., Moore A.C., Walther M., Laidlaw S.M., Peto T., Skinner M.A., Gilbert S. C., Hill A.V.S.; (2006) 'Safety of Recombinant Fowlpox Strain 9 and Modified Vaccinia Virus Ankara Vaccines Against Liver-Stage P. falciparum Malaria in Non-Immune Volunteers'. Vaccine, (24):3026-3034 Globe icon [DOI] [Details]
(2005)'Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance'
Moore A.C., Gallimore A., Draper S., Watkins K.R., Gilbert S.C. and Hill A.V.S. ; (2005) 'Anti-CD25 Antibody Enhancement of Vaccine-Induced Immunogenicity: Increased Durable Cellular Immunity with Reduced Immunodominance'. Journal of Immunology, (175):7264-7273 Globe icon [Details]
(2005)'Novel Protein and Poxvirus Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell Mediated Immunity'
Hutchings C.L, Gilbert S.C., Hill A.V.S and Moore A.C.; (2005) 'Novel Protein and Poxvirus Based Vaccine Combinations for Simultaneous Induction of Humoral and Cell Mediated Immunity'. Journal of Immunology, (175):599-606 Globe icon [Details]
(2004)'Progress in DNA-based heterologous prime-boost immunization strategies for malaria'
Moore AC, Hill AV; (2004) 'Progress in DNA-based heterologous prime-boost immunization strategies for malaria'. Immunological reviews, 199 :126-143 Globe icon [DOI] [Details]
(2004)'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses'
Prieur E, Gilbert S.C., Schneider J ., Moore A.C. , Sheu E.G, Goonetilleke N., Robson K.J.H., and Hill A.V. ; (2004) 'A Plasmodium falciparum candidate vaccine based on a six-antigen polyprotein encoded by recombinant poxviruses'. Proceedings of The National Academy of Sciences of The United States of America, (101):290-295 Globe icon [DOI] [Details]
(2004)'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells'
Behboudi S., Moore A.C. and Hill A.V.S. ; (2004) 'Splenic dendritic cell subsets prime and boost CD8 T cells and are involved in the generation of effector CD8 T cells'. Cellular Immunology, (228):15-19 Globe icon [DOI] [Details]
(2004)'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction'
Behboudi S., Moore A.C., Gilbert S., Nicoll C.L. and Hill A.V.S. ; (2004) 'Dendritic cells infected by recombinant modified vaccinia virus Ankara retain immunogenicity in vivo despite in vitro dysfunction'. Vaccine, 22 :4326-4331 Globe icon [DOI] [Details]
(2002)'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice'
Moore AC, Kong WP, Chakrabarti BK, Nabel GJ; (2002) 'Effects of antigen and genetic adjuvants on immune responses to human immunodeficiency virus DNA vaccines in mice'. Journal of virology, 76 (1):243-250 Globe icon [DOI] [Details]
(2000)'Inhibition of Interleukin-12 production in human monocyte-derived macrophages by Tumor Necrosis Factor'
Ma X., Sun J., Papasavvas E., Riemann H., Robertson S., Marshall J., Bailer R.T., Moore A.C., Donnelly R., Trinchieri G., Montaner L.J.,; (2000) 'Inhibition of Interleukin-12 production in human monocyte-derived macrophages by Tumor Necrosis Factor'. Journal of Immunology, 164 :1722-1729 Globe icon [Details]
(1999)'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1'
Moore A, McCarthy L, Mills KH; (1999) 'The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1'. Vaccine, 17 (20-21):2517-2527 [Details]
(1998)'Approaches to new vaccines'
Mahon BP, Moore A, Johnson PA, Mills KH.; (1998) 'Approaches to new vaccines'. Critical Review of Biotechnology, 18 (4):257-282 [Details]
(1995)'An adjuvant formulation that switches Th2 to Th1 responses with soluble recombinant HIV proteins'
Moore A, Adams S., Garcon N., Delchambre M., Thriart C., Bruck C. and Mills KH.; (1995) 'An adjuvant formulation that switches Th2 to Th1 responses with soluble recombinant HIV proteins'. Immunology, 86 [Details]
(1995)'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells'
Moore A, McGuirk P, Adams S, Jones WC, McGee JP, O'Hagan DT, Mills KH.; (1995) 'Immunization with a soluble recombinant HIV protein entrapped in biodegradable microparticles induces HIV-specific CD8+ cytotoxic T lymphocytes and CD4+ Th1 cells'. Vaccine, 13 (18):1741-1749 [Details]
(1994)'Factors affecting Th1 and Th2 cell induction and immunoglobulin class switching in the immune response to HIV proteins'
Moore A.C., Adams S., and Mills K.H.G.; (1994) 'Factors affecting Th1 and Th2 cell induction and immunoglobulin class switching in the immune response to HIV proteins'. Immunology, 83, S1 [Details]

Other Journals

 YearPublication
(2010)'Development of Stabilised Vaccines with Needle-Free Devices for Targeted Skin Immunization'
A. Crean, C. O’Mahony and A. C. Moore (2010) 'Development of Stabilised Vaccines with Needle-Free Devices for Targeted Skin Immunization' European Pharmaceutical Review, 15 (6) :56-60. [Details]

Conference Publications

 YearPublication
(2011)38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society
McGrath, M. G.,O'Mahony, C.,Vrdoljak, A.,Moore, A. C.,Crean, A. (2011) Design of Dissolvable Microneedles for Drug DeliveryDesign of Dissolvable Microneedles for Drug Delivery 38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USAMaryland, USA, [Details]
(2011)Skin Vaccination Summit 2011Skin Vaccination Summit 2011
Moore, A. C.,Pearson, F.,Vrdoljak, A.,McGrath, M. G.,Draper, S.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2011) Development of silicon and dissolvable ImmuPatch microneedle devices for vaccinationDevelopment of silicon and dissolvable ImmuPatch microneedle devices for vaccination Skin Vaccination Summit 2011Skin Vaccination Summit 2011 Washington, USAWashington, USA, [Details]
(2011)38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society
Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,Crean, A.,O'Mahony, C.,Hill, A. V. S.,Moore, A. C. (2011) Immunization using ImmuPatch silicon microneedles results in enhanced T-cell and antibody responses compare to traditional imunization routesImmunization using ImmuPatch silicon microneedles results in enhanced T-cell and antibody responses compare to traditional imunization routes 38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USAMaryland, USA, [Details]
(2011)38th Annual Meeting Controlled Release Society
M.G. McGrath, C.O¿Mahony, A. Vrdoljak, A.C. Moore, A.M. Crean; (2011) Design of Dissolvable Microneedles for Drug Delivery 38th Annual Meeting Controlled Release Society National Harbor, Maryland, U.S.A, [Details]
(2011)38th Annual Meeting Controlled Release Society
John B. Carey, Frances E. Pearson, Anto Vrdoljak, Abina M. Crean, Conor O¿Mahony, Adrian V.S. Hill, Anne C. Moore; (2011) Immunization using ImmuPatch Silicon Microneedle Arrays results in Enhanced T 38th Annual Meeting Controlled Release Society National Harbor, Maryland, U.S.A, [Details]
(2011)38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society
Vrdoljak, A.,McGrath, M. G.,Crean, A.,O'Mahony, C.,Moore, A. C. (2011) Development of ImmuPatch arrays coated with live vaccineDevelopment of ImmuPatch arrays coated with live vaccine 38th Annual Meeting and Exposition of the Controlled Release Society38th Annual Meeting and Exposition of the Controlled Release Society Maryland, USAMaryland, USA, [Details]
(2011)Skin Vaccination Summit 2011Skin Vaccination Summit 2011
O'Mahony, C.,Moore, A. C.,Blake, A.,Scully, J.,O'Brien, J.,Hegarty, M. (2011) Silicon microneedles for vaccine deliverySilicon microneedles for vaccine delivery Skin Vaccination Summit 2011Skin Vaccination Summit 2011 Washington, USAWashington, USA, [Details]
(2010)First International Conference on Microneedles
Moore A.C., Carey J.B., Pearson F., Vrdoljak A., McGrath M., Draper Simon J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C; (2010) Enhanced Immune Responses induced by ImmuPatch Transcutaneous Vaccination First International Conference on Microneedles Atlanta, [Details]
(2010)12th International Conference on Perspectives in Percutaneous Penetration
M. G. McGrath, C. O¿Mahony, J. B. Carey, A. Vrdoljak, A. C. Moore and A. M. Crean; (2010) Spray Coating of Silicon Microneedle Patches for Intradermal Drug Delivery 12th International Conference on Perspectives in Percutaneous Penetration [Details]
(2010)First International Conference on Microneedles
McGrath M., Vrdoljak A., O¿Mahony C., Carey J.B., Moore A.C., Crean A.; (2010) Percutaneous Vaccine Delivery Using Microneedles First International Conference on Microneedles Atlanta, [Details]
(2010)Microneedles 2010Microneedles 2010
Pearson, F. E.,Reyes-Sandoval, A.,O'Mahony, C.,Moore, A. C.,Hill, A. V. S. (2010) Delivery of Recombinant Adenoviral Vector malaria vaccines by ImmuPatch Induces Protective CD8+ T-cell Mediated Immunity Against Parasite ChallengeDelivery of Recombinant Adenoviral Vector malaria vaccines by ImmuPatch Induces Protective CD8+ T-cell Mediated Immunity Against Parasite Challenge Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details]
(2010)Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010)
O'Mahony, C.,Blake, A.,Scully, J.,O'Brien, J.,Moore, A. C. (2010) Silicon Microneedles for Painless Percutaneous PenetrationSilicon Microneedles for Painless Percutaneous Penetration Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010) La Grande Motte, FranceLa Grande Motte, France, [Details]
(2010)Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010
O'Mahony, C.,Blake, A.,Scully, J.,O'Brien, J.,Moore, A. C. (2010) Silicon Microneedles for Painless Percutaneous PenetrationSilicon Microneedles for Painless Percutaneous Penetration Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 Cork, IrelandCork, Ireland, [Details]
(2010)MMVAM 2010
Moore, A. C.,Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Draper, S. J.,Gilbert, S. C.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2010) Enhanced T-cell and Antibody Responses Induced by ImmuPatch Transdermal Vaccination MMVAM 2010 Dublin, IrelandDublin, Ireland, [Details]
(2010)Microneedles 2010Microneedles 2010
Moore, A. C.,Carey, J. B.,Pearson, F. E.,Vrdoljak, A.,McGrath, M. G.,Draper, S. J.,Gilbert, S. C.,Hill, A. V. S.,Crean, A.,O'Mahony, C. (2010) Enhanced Immune Responses Induced by ImmuPatch Transcutaneous VaccinationEnhanced Immune Responses Induced by ImmuPatch Transcutaneous Vaccination Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details]
(2010)4th Vaccine and ISV Annual Global Congress4th Vaccine and ISV Annual Global Congress
Moore, A. C.,Carey, J. B.,Crean, A.,Vrdoljak, A.,McGrath, M. G.,O'Mahony, C. (2010) Percutaneous Immunization using ImmuPatch: Needle-free vaccination that results in stronger T-cell and antibody responses compared to traditional immunization routesPercutaneous Immunization using ImmuPatch: Needle-free vaccination that results in stronger T-cell and antibody responses compared to traditional immunization routes 4th Vaccine and ISV Annual Global Congress4th Vaccine and ISV Annual Global Congress Vienna, AustriaVienna, Austria, [Details]
(2010)Microneedles 2010Microneedles 2010
McGrath, M. G.,Vrdoljak, A.,O'Mahony, C.,Carey, J. B.,Moore, A. C.,Crean, A. (2010) Percutaneous vaccine Delivery Using MicroneedlesPercutaneous vaccine Delivery Using Microneedles Microneedles 2010Microneedles 2010 Atlanta, USAAtlanta, USA, [Details]
(2010)Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010)
McGrath, M. G.,O'Mahony, C.,Carey, J. B.,Vrdoljak, A.,Moore, A. C.,Crean, A. (2010) Percutaneous Immunization Using ImmuPatch: Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical ModelPercutaneous Immunization Using ImmuPatch: Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical Model Perspectives in Percutaneous Penetration (PPP 2010)Perspectives in Percutaneous Penetration (PPP 2010) La Grande Motte, FranceLa Grande Motte, France, [Details]
(2010)Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010
Carey, J. B.,Moore, A. C.,McGrath, M. G.,Pearson, F.,Hill, A. V. S.,Moore, A. C. (2010) Percutaneous Immunization using Immupatch; Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical ModelPercutaneous Immunization using Immupatch; Comparison of Vaccine Localisation and Induction of Antibody and T-cell responses in a Pre-clinical Model Molecules to Medicine Conference 2010Molecules to Medicine Conference 2010 Cork, IrelandCork, Ireland, [Details]
(2009)Big Ideas Showcase 2009
Moore, A. C.,Carey, J. B..,Vrdoljak, A.,McGrath, M. G.,Crean, A.,O'Mahony, C. (2009) ImmuPatch: Innovative Solutions to Vaccine Delivery Barriers Big Ideas Showcase 2009 Dublin, IrelandDublin, Ireland, [Details]

Published Reports

 YearPublication
(2006)The use of non-human primates in research, chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society.
Sir David Weatherall; (2006) The use of non-human primates in research, chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society. Wellcome Trust, MRC, The Royal Society, UK. [Details]

Honours and Awards

 YearTitleAwarding Body
2013Joint Winner "Get Started Technology Venture Programme" SFI
2012UCC Research Team of the Year UCC

Professional Associations

 AssociationFunctionFrom / To
Burroughs-Wellcome sponsored; "Malaria Liver-stage Genomics and Proteomics", Washington DC Contributor/
"The use of non-human primates in research", chaired by Sir David Weatherall. Report to Wellcome Trust, MRC, Academy of Medical Sciences, The Royal Society Consultee to the working group/
Livestock Vaccine Enterprise Initiative Meeting, Wellcome Trust Centre for Human Genetics Invited delegate to initiate international veterinary vaccine consortium17-MAY-07 / 18-MAY-07
New Trends in Cancer Immunotherapy. Fondation Merieux Invited Participant08-JUL-07 / 11-JUL-07

Patents

 Patent NumberTitleInventorGranted
WO2004110482Combination Vaccines Moore A.C., Nicoll C.L, Hill A.V.S26-OCT-06
WO2005115451METHODS FOR GENERATING IMPROVED IMMUNE RESPONSE MOORE ANNE CLARE; HILL ADRIAN V S08-DEC-05
UK1007204.9Microneedle Array O¿Mahony C. and Moore, A.C.29-APR-10
UK 1007207.2Microneedle kits for vaccine delivery Moore A.C., Carey J.B., Pearson F., McGrath, M., Crean A., Hill A.V.S and O¿Mahony, C.,29-APR-10
GB1107642.9Method for making dissolvable microneedle patches A. Vrdoljak, A. Moore09-MAY-11
GB1019577.4Method to prepare dissolvable microneedles. Crean A., O’Mahony, C. McGrath, M., Vrdoljak, A. Moore A.C18-NOV-10

Conference Contributions

 YearPublication
(2014)Third International Conference on Microneedles,,
Anne Moore (2014) Third international meeting on microneedles. [Invited Lectures (Conference)], Third International Conference on Microneedles,, Baltimore, MD, USA, , 19-MAY-14 - 21-MAY-14. [Details]
(2013)“The pig as model in human vaccine development,
Anne Moore (2013) Pig as a model for intradermal vaccination. [Invited Lectures (Workshops)], “The pig as model in human vaccine development, Central Veterinary Institute in Lelystad, NL , 20-SEP-03. [Details]
(2012)2nd International Conference on Microneedles: Microneedles 2012,
A. M. Crean, M. G. McGrath, C. O’Mahony, A. Vrdoljak and A. C. Moore (2012) Dissolvable ImmuPatch Microneedles for Drug Delivery. [Poster Presentation], 2nd International Conference on Microneedles: Microneedles 2012, Cork , 13-MAY-12 - 15-MAY-12. [Details]
(2011)Skin Vaccine Summit,
Anne Moore; (2011) Development of Silicon and Dissolvable ImmuPatch Microneedle Devices for Vaccination. [Oral Presentation], Skin Vaccine Summit, Washington DC , 12-OCT-11 - 14-OCT-11. [Details]
(2011)Insights into Successful Translational Research,
Anne Moore (2011) SFI/HRB/MMI organised national meeting. [Invited Seminars/Guest Lectures], Insights into Successful Translational Research, Dublin , 29-NOV-11. [Details]
(2011)PharmSciFair,
A Moore; (2011) Development of Silicon and Dissolvable ImmuPatch Microneedle Devices for Vaccination. [Invited Oral Presentation], PharmSciFair, Prague , 11-OCT-11 - 14-OCT-11. [Details]
(2010)Modern Mucosal Vaccines and Adjuvants,
Moore A.C., Carey J.B, Pearson F.E., Vrdoljak A., McGrath M., Draper S.J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C. ; (2010) Enhanced T cell and Antibody Responses induced by ImmuPatch Transdermal Vaccination. [Oral Presentation], Modern Mucosal Vaccines and Adjuvants, Dublin, Ireland , 28-APR-10 - 30-APR-10. [Details]
(2010)Perspectives in Percutaneous Penetreation,
Moore A.C., Carey J.B., McGrath M. Pearson F.E., Vrdoljak A. Hill A.V.S., Crean A. and O¿Mahony C. ; (2010) Percutaneous immununization using ImmuPatch: Comparison of vaccine localisation and induction of antibody and T cell responses in a pre-clinical model. [Poster Presentation], Perspectives in Percutaneous Penetreation, La Grande Motte, France, , 06-APR-10 - 10-APR-10. [Details]
(2010)Perspectives in Percutaneous Penetreation,
McGrath M., O¿Mahony C., Carey J.B., Vrdoljak A., Moore A.C. and Crean A; (2010) Spray Coating of Silicon Microneedle Patches for Intradermal Drug Delivery. [Poster Presentation], Perspectives in Percutaneous Penetreation, La Grande Motte, France , 06-APR-10 - 08-APR-10. [Details]
(2010)First International Conference on Microneedles,
Pearson F.E., Reyes-Sandoval A.,. O'Mahony C, Moore A.C., Hill A.V.S, ; (2010) Delivery of Recombinant Adenoviral Vector Malaria Vaccines by ImmuPatch Induces Protective CD8+ T Cell Mediated Immunity Against Parasite Challenge. [Poster Presentation], First International Conference on Microneedles, Atlanta, Georgia, , 24-MAY-10 - 26-MAY-10. [Details]
(2010)First International Conference on Microneedles,
McGrath M., Vrdoljak A., O¿Mahony C., Carey J.B., Moore A.C. and Crean A.; (2010) Percutaneous Vaccine Delivery Using Microneedles. [Poster Presentation], First International Conference on Microneedles, Atlanta, Georgia, , 24-MAY-10 - 26-APR-10. [Details]
(2010)First International Conference on Microneedles,
Moore A.C., Carey J.B., Pearson F., Vrdoljak A., McGrath M., Draper S.J., Gilbert S.C., Hill A.V.S., Crean A. and O¿Mahony C., ; (2010) Enhanced Immune Responses induced by ImmuPatch Transcutaneous Vaccination. [Oral Presentation], First International Conference on Microneedles, Atlanta, Georgia , 24-MAY-10 - 26-MAY-10. [Details]
(2010)4th Vaccine and ISV Annual Global Congress,
A.C. Moore, J. Carey, F. Pearson, A. Vrdoljak, M. McGrath, S. Draper, S. Gilbert, A. Hill, A. Crean and C. O¿Mahony; (2010) Percutaneous Immunization using ImmuPatch: Needle-free vaccination that results in stronger T cell and antibody responses compared to traditional immunization routes. [Oral Presentation], 4th Vaccine and ISV Annual Global Congress, Vienna, Austria , 03-OCT-10 - 05-OCT-10. [Details]
(2010)Perspectives in Percutaneous Penetreation,
O'Mahony C, Blake A., Scully J., O'Brien J. and Moore A.C; (2010) Silicon Microneedles for Painless Percutaneous Penetration. [Poster Presentation], Perspectives in Percutaneous Penetreation, La Grande Motte, France , 06-APR-10 - 10-APR-10. [Details]
(2009)Modern Vaccines adjuvants and Delivery Systems,
Carey J.B., Gilbert S.C., Vrdoljak, A., Hill A.V.S and Moore A.C; (2009) T cell inducing flu vaccines; Protective Efficacy and Strain Specificity. [Poster Presentation], Modern Vaccines adjuvants and Delivery Systems, Vienna, Austria , 28-OCT-09 - 30-OCT-09. [Details]
(2009)European Congress of Immunology,
Carey J.B., Gilbert S.C., A., Hill A.V.S and Moore A.C. ; (2009) Immunogenicity and protective efficacy of a viral vectored candidate human pandemic influenza vaccine. [Oral Presentation], European Congress of Immunology, European Congress of Immunology, Berlin, Germany, , 13-SEP-09 - 16-SEP-09. [Details]
(2009)2nd Annual Oxford Avian Influenza Conference, BirdFlu2009,
Carey J.B., Gilbert S.C., A., Hill A.V.S and Moore A.C ; (2009) Pre-clinical assessment of a candidate T cell inducing viral vectored vaccine for human influenza viru. [Oral Presentation], 2nd Annual Oxford Avian Influenza Conference, BirdFlu2009, Oxford, UK , 10-SEP-09 - 11-SEP-09. [Details]
(2007)Unknown,
Moore, A. C. ; (2007) Anti-CD25 Antibody Enhancement of Vaccine-induced immunogenicity; translation form Mouse to Primates. [Oral Presentation], Unknown, Cork, Ireland , 01-JUN-07 - 01-JUN-07. [Details]
(2007)Vaccine Induced Immunity to Fight Disease,
Moore, A. C. ; (2007) unknown. [Oral Presentation], Vaccine Induced Immunity to Fight Disease, Biochemistry Dept., UCC, , 01-APR-07 - 01-APR-07. [Details]
(2007)T cell Inducing Influenza Virus Vaccines,
Moore A.C., Gallimore A., Draper S., Watkins K.R., Gilbert S.C. and Hill A.V.S. ; (2007) unknown. [Oral Presentation], T cell Inducing Influenza Virus Vaccines, University of Johannesburg , 01-OCT-07 - 01-OCT-07. [Details]
(2006)Malaria and TB Vaccines; Modulating, Protective and Regulatory T cell responses,
Moore, A. C. ; (2006) Control of anti-tumoral and anti-infectious immune responses by Regulatory T cell subsets: potential clinical applications. [Oral Presentation], Malaria and TB Vaccines; Modulating, Protective and Regulatory T cell responses, Annecy, France , 01-SEP-06 - 01-SEP-06. [Details]
(2005)Tropical Network Meeting,
Moore, A. C. ; (2005) Improving Immunogenicity by Deregulating Malaria Vaccines. [Oral Presentation], Tropical Network Meeting, Kilifi, Kenya , 01-SEP-05 - 01-SEP-05. [Details]
(2005)Virus Vector Based Vaccines,
Moore, A. C. ; (2005) unknown. [Oral Presentation], Virus Vector Based Vaccines, University of Nottingham , 01-APR-05 - 01-APR-05. [Details]
(2005)Assaying Potency of Novel Vaccines,
Moore, A. C. ; (2005) Potency of Poxviral Based Vectors for Malaria and TB vaccines. [Oral Presentation], Assaying Potency of Novel Vaccines, NIH, Bethesda, MD , 01-OCT-05 - 01-OCT-05. [Details]
(2005)British Council, INYS meeting,
Moore, A. C. ; (2005) Progress in Virus Vector based Malaria and TB vaccines. [Oral Presentation], British Council, INYS meeting, Dunedin, New Zealand , 01-MAR-05 - 01-MAR-05. [Details]
(2004)Keystone Symposium: Rational Design of Vaccines and Immunotherapeutics,
Moore, A. C. ; (2004) PRE-EXISTING FOWLPOX IMMUNITY IS LESS INHIBITORY TO HETEROLOGOUS PRIME-BOOST VACCINE STRATEGIES COMPARED TO ANTI-MVA IMMUNITY. [Oral Presentation], Keystone Symposium: Rational Design of Vaccines and Immunotherapeutics, Keystone Resort, Keystone, Colorado , 01-MAR-04 - 01-MAR-04. [Details]
(2004)University of Wales College of Medicine BSI seminar series,
Moore, A. C. ; (2004) Prime Boost Malaria Vaccines. [Oral Presentation], University of Wales College of Medicine BSI seminar series, Wales , 01-DEC-04 - 01-DEC-04. [Details]
(2004)British Society for Immunology,
Moore, A. C. ; (2004) Progress in Malaria and TB vaccines; improved de-regulated vaccine strategies. [Oral Presentation], British Society for Immunology, Harrogate, UK , 01-DEC-04 - 01-DEC-04. [Details]

Disclosures

 TitleInventorSubmitted
T cell inducing influenza virus vaccines. Gilbert S.C., Moore A.C., and Hill A.V.S28-SEP-07
Method of fabrication and composition of dissolvable microneedles. Crean A, McGrath M., Vrdoljak A, O¿Mahony C. and Moore A.C Submitted April 201021-APR-10
Method of fabrication and composition of dissolvable microneedle patches Vrdoljak A, Crean A, McGrath M., O¿Mahony C. and Moore A.C21-APR-10
Methods of modulating cell surface expression of the IL-2 receptor Dev K.K., Moore A.C24-JUN-08

Committees

 CommitteeFunctionFrom / To
School of Pharmacy, Research and Graduate Studies Committee Chair2008 /
School of Pharmacy, Research Quality Review Committee Vice-Chair2008 / 2009
School of Pharmacy, Quality Review Committee Vice-Chair2008 / 2009
College of Medicine and Health Research Committee Member2009 /
UCC Genetically Modified Biological Organisms Committee. Member2009 /
College of Medicine and Health Graduate School Committee Member2010 /

Employment

 EmployerPositionFrom / To
University College Cork Lecturer01-JAN-07 /
University of Oxford Senior Immunologist01-JAN-02 / 01-JAN-06
University of Oxford Postdoctoral Associate01-JAN-01 / 01-JAN-02
University of Michigan Postdoctoral Associate01-JAN-98 / 01-JAN-01
The Wistar Institute, Philadelphia, USA Postdoctoral Scientist01-SEP-97 / 31-JUL-98

Consultancy

 ClientDescription
Grand Challenge for Global Health research team, Oxford University

Outreach Activities

 Description

Erasmus Co-ordinator, School of Pharmacy (Dec 2007-present).

Reviews

 JournalRole
Plos One Member of Editorial Board
Vaccine Referee
Expert Review Of Vaccines Referee
Immunological Reviews Referee

PT6401: Pharmacology for M.Sc. in Pharmaceutical Technology and Quality Systems
PT4447; Advanced Pharmacology
PT3445; Clinical Pharmacology
PF4004: lectures on animal ethics
PT2447: Molecular Pharmacology
PT1445: Foundatin Pharmacology

 StudentDegree TypePrimary
Allen Evin Anthony Doctoral DegreeYes
 Term (ID))TitleLinkSubject
2015Pharmacology PT6401Pharmacology
2015Molecular Pharmacology PT2447Molecular Pharmacology
2015Foundation Pharmacology PT1445Foundation Pharmacology
2015Advanced Pharmacology and Veterinary Pharmacology PT4447Advanced Pharmacology and Veterinary Pharmacology